NextCell Pharma publishes its Interim Report 3 2024/2025

July 24, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 – May 31, 2025. This English version of the Interim Report is a translation of the Swedish version. The Swedish version is the official version.
The report is available on the company's website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third Quarter (2025-03-01 to 2025-05-31)

Operating income amounted to 2,262 (2,482) TSEK, of which Cellaviva contributed 2,261 (2,442) TSEK.
Net sales amounted to 2,261 (2,442) TSEK.
Profit/loss after financial items amounted to -10,271 (-8,822) TSEK.
Earnings per share* were -0.14 (-0.26) SEK.
Cash and cash equivalents amounted to 16,710 (20,797) TSEK.
Equity ratio** amounted to 79 (77) percent.

First Nine Months (2024-09-01 to 2025-05-31)

Operating income amounted to 8,542 (9,582) TSEK, of which Cellaviva contributed 8,338 (9,022) TSEK.
Net sales amounted to 8,338 (9,022) TSEK.
Profit/loss after financial items amounted to -26,511 (-28,710) TSEK.
Earnings per share* were -0.36 (-0.84) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the third quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first nine months of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 31 May 2025: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the third quarter

● At the end of March, NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been elected to the Board of Directors of ATMP Sweden.

● At the beginning of April, NextCell published preliminary 1-year results from the older age group (12–21 years) in the ongoing ProTrans-Young clinical study. The study evaluates the safety and efficacy of the company's cell therapy ProTrans in preserving insulin production in young individuals with newly diagnosed type 1 diabetes, compared to placebo.

● NextCell announced in early April that Dr. Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the international industry organization International Society for Cell and Gene Therapy (ISCT).

● At the beginning of May, the company announced that a recently published clinical study showed promising results for mesenchymal stromal cells (MSCs) in the treatment of mild Alzheimer's disease. The study is a phase 2a study and is published in Nature Medicine (Rash et al., 2025) The results strengthen the scientific basis for NextCell's drug candidate ProTrans, which is being developed for autoimmune and inflammatory diseases.

● NextCell announced in mid-May that Eric Strati PharmD, MBA, joins NextCell's Board of Advisors to support the commercial strategy for ProTrans

● In mid-May, NextCell announced that it had entered into a strategic partnership with Fujifilm Irvine Scientific Inc. to bring together their core competencies in mesenchymal stromal cells (MSCs) and life science raw materials. The goal of the collaboration is a comprehensive offering to researchers, biotech and pharmaceutical companies in the cell therapy field – standardized MSC products, optimized cell culture and solutions for cryopreservation.

● At the end of May, the company announced that it hadbeen granted a US patent for the MSC prediction algorithm. The patent protects NextCell's innovative method for predicting the effect of treatment with mesenchymal stromal cells (MSCs) in individual patients and for developing individualized treatment options based on this prediction.

● At the end of May, the company further announced that Angela Vollstedt, PhD, MBA, will join NextCell's Board of Advisors to strengthen the company's strategy for manufacturing and licensing.

Significant events and news after the reporting period

● At the beginning of June, the Company announced the outcome of the exercise of TO2 and resolved on directed share issues to guarantors, Through the exercise of the Warrants and the Directed Issue, the Company will receive a total of approximately SEK 36.6 million before deduction of issue costs. Furthermore, the Board of Directors has resolved on a set-off issue of 1,742,100 shares to the guarantors for payment of the guarantee fee.

● The Company announced in early June that all patients in the ongoing ProTrans-Young clinical study had been treated. A milestone that marks the completion of dosing in the company's largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the company's lead cell therapy candidate, ProTrans, for the treatment of children and adolescents with newly diagnosed type 1 diabetes.Cell and Gene Therapy (ISCT).

● In Mid-July the company summoned to an Extra General Meeting on August 21^st in order to change the company's fiscal year to be aligned with the calendar year.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 24-07-2025 07:00 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachment Read full press release on Cision (external link)

2019-09-24

Last patient, last visit completed in the dose escalation part

NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial. ProTrans-1 is a two-part phase I / II clinical trial where the phase I part evaluates safety for three doses. All nine patients have now been followed up for 12 months and have left the study. As previously communicated, all 15 patients in the phase II part of ProTrans-1 have been treated and will be followed for 12 months. The second part is randomized,

Read more Read more

2019-09-12

Update on the ongoing clinical trials

NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial after 12 months follow-up. The ProTrans-Repeat has included 5 out of 18 patients. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat type-1 diabetes. A single dose of ProTrans is given and the patients own ability to produce insulin is compared

Read more Read more

2019-08-16

NextCell Pharma files another patent application

NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the central nervous system. The application was submitted to the Swedish Patent and Registration Agency on August 15 and is formulated to cover the general production of all types of mesenchymal stem cell products derived from multiple donors and cells selected by the selection algorithm. Furthermore, the

Read more Read more

2019-07-31

Interim report 2018-09-01 - 2019-05-31

Third quarter report By "NextCell", “NXTCL” or "Company" is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight" refers to the Spotlight Stock Market (previous AktieTorget). Amount in brackets refer to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31. This English version is a translation of the Swedish version. The Swedish version is at all time to be seen as the leading document. Nine months (2018-09-01 until 2019-05-31) · Operating income amounted to SEK 1 410 055 (527 545). · Operating result

Read more Read more

2019-06-20

Final patient treated in the phase II part of the ProTrans-1 trial

NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available. The final patient has been treated in the randomized, placebo controlled ProTrans-1 phase II part trial. Efficacy and safety data will be collected through regular clinical assessments visits during a 12 month period. Last patient, last will be assessed in July 2020 and thereafter the code will be

Read more Read more

2019-06-20

New collaboration and increased digital presence - Cellaviva is gearing for growth

NextCell Pharma AB ("NextCell") today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB ("Bonzun"), who are providing the first global health app for pregnant women. Bonzun has launched the first virtual midwife for pregnant women which can be downloaded in Appstores under the name Bonzun Pregnant. The app is currently available in 79 countries worldwide under the name Bonzun and in Sweden under the name Min Graviditet. The collaboration has been entered into with the common goal of strengthening the work of sharing knowledge

Read more Read more

2019-06-19

NextCell has treated the first patient in the ProTrans-Repeat trial

NextCell Pharma AB (NextCell) announces that earlier today the first patient was treated as part of the ProTrans-Repeat trial, which is NextCell’s second clinical trial. ProTrans-Repeat is a Phase IIa clinical trial which includes patients receiving active treatment with ProTrans and who have previously been treated in the ProTrans-1 study's dose escalation phase. This means that the participants receive their second treatment with ProTrans, just over a year after the first. The goal of the ProTrans-Repeat trial is to test whether repeated treatment can increase or maintain the effect of

Read more Read more

2019-06-11

Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue

The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers ownership in NextCell after the investments increases from approximately SEK 3.6 million to 6.0 million. Regarding the ongoing rights issue in NextCell, the principal owner Anders Essen-Möller, also the chairman of the company, has chosen to fully utilize its allotted subscription rights, which means that he

Read more Read more